Atractyloside inhibits gefitinib‑resistant non‑small‑cell lung cancer cell proliferation.
BORIS
NSCLC
TKI-resistant
atractyloside
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
28
11
2023
accepted:
23
05
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
Atractyloside is a traditional Chinese medicine used to treat nasal congestion, and allergic rhinitis; however, its effects on cancer are unknown. Non-small cell lung cancer (NSCLC) is associated with high mortality rates worldwide, and relapse due to epidermal growth factor receptor mutations is a problem in clinical therapy. Therefore, novel biomarkers are required for the diagnosis and treatment of NSCLC. Brother of the regulator of imprinted sites (
Identifiants
pubmed: 39119229
doi: 10.3892/ol.2024.14599
pii: OL-28-4-14599
pmc: PMC11306992
doi:
Types de publication
Journal Article
Langues
eng
Pagination
466Informations de copyright
Copyright: © 2024 Yao et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.